Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 862112
                    [Title] => Novartis drug offers new tack in cancer treatment
                    [Summary] => 
Endocrine therapy remains the cornerstone of treatment for postmenopausal women with hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer.

                    [DatePublished] => 2012-11-01 00:00:00
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => http://imageshack.us/a/img27/6591/scitec4newthumb.jpg
                )

        )

)

CAMPONE

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 862112
                    [Title] => Novartis drug offers new tack in cancer treatment
                    [Summary] => 
Endocrine therapy remains the cornerstone of treatment for postmenopausal women with hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer.

                    [DatePublished] => 2012-11-01 00:00:00
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => http://imageshack.us/a/img27/6591/scitec4newthumb.jpg
                )

        )

)

abtest

Novartis drug offers new tack in cancer treatment

November 1, 2012 - 12:00am

Endocrine therapy remains the cornerstone of treatment for postmenopausal women with hormone receptor-positive (HR+), HER2/neu-negative...

Science and Environment